Profile of selumetinib and its potential in the treatment of melanoma

Dae Won Kim
Sapna P Patel
Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Abstract: The mitogen-activated protein kinase (MAPK) pathway is a critical oncogenic driver signal in a number of malignancies. The discovery of activating mutations in the MAPK pathway has led to the development of MAPK pathway inhibitors. Selumetinib is a potent and selective inhibitor of MEK1 and MEK2, which are essential downstream molecules in the MAPK pathway. Several preclinical and clinical studies have demonstrated the promising antitumor activity of selumetinib. In this review, we discuss the MAPK pathway in melanoma and summarized data from preclinical and clinical studies of selumetinib for advanced melanoma.

Keywords: selumetinib, MEK inhibitor, melanoma, uveal melanoma

Introduction
Melanoma is the most aggressive skin cancer, and both the incidence of melanoma and melanoma-related deaths have increased over the last several decades in the United States, with more than 76,000 new cases and more than 9,000 deaths predicted in 2013.1 A majority of patients with melanoma are diagnosed early with local disease, and surgical resection is the mainstay of treatment for localized melanoma with excellent outcome. In contrast, patients with metastatic melanoma have poor outcomes, with a 6–8 month median survival.2 Furthermore, the treatment for advanced melanoma is quite challenging. Until 2011, only two drugs, dacarbazine and recombinant human high-dose interleukin 2, were approved for the treatment of metastatic melanoma by the US Food and Drug Administration (FDA). Unfortunately, both drugs have a low response rate (5%–15%), and high-dose interleukin 2 also is associated with significant systemic toxicities.3

The rapid technical advancement in molecular biology and tumor immunology led to new treatment approaches such as targeted therapy and immunotherapy. Ipilimumab, a monoclonal anticytotoxic T-lymphocyte-associated antigen 4 antibody, was approved by the FDA in 2011 on the basis of significant improvement in progression-free survival (PFS) and overall survival (OS) compared with gp100 vaccine treatment.4 Recently, mitogen-activated protein kinase (MAPK) pathway inhibitors, including selective BRAF inhibitors (dabrafenib and vemurafenib) and a selective MEK inhibitor (trametinib), have shown significant improvement of PFS and OS over chemotherapy in patients with BRAF mutant melanoma, which led to the approval of these drugs.5–7 Despite these promising new agents, the majority of metastatic melanomas are not curable. Therefore, effective and novel approaches are still desperately needed for metastatic melanoma.
MAPK pathway

One of the biggest milestones in melanoma research is the identification of \textit{BRAF} gene mutations in melanoma.\textsuperscript{a}\textsuperscript{a} \textit{BRAF} is one of the key molecules in the MAPK pathway, which is frequently dysregulated in human cancer.\textsuperscript{9} MAPK pathway, composed of RAS-RAF-MEK-ERK, is associated with cell proliferation and growth (Figure 1). Up to 75\% of melanomas have dysregulated MAPK signaling pathway via \textit{BRAF} (50\%) or \textit{NRAS} mutations (15\%–25\%), which results in unregulated cell proliferation and growth.\textsuperscript{8,10}

MEK inhibition

Dysregulation of MAPK pathway in the majority of melanoma and other malignancies, including colon, pancreatic, and non-small-cell lung cancer, makes MEK an attractive therapeutic target as one of the main downstream molecules of MAPK pathway. Initial preclinical studies of selective MEK inhibitors have been shown to have promising antitumor activities in \textit{BRAF} and \textit{NRAS} mutant tumor cell lines.\textsuperscript{11,12} Solit et al showed complete abrogation of \textit{BRAF} mutant melanoma growth and partial inhibition of \textit{NRAS} mutant melanoma growth in murine xenografts with selective MEK inhibitors such as CI-1040 and PD0325901.\textsuperscript{12} However, clinical development of these MEK inhibitors, including CI-1040 and PD0325901, was discontinued because of a lack of clinical activity of CI-1040 and severe and frequent neurologic, musculoskeletal, and ocular toxicities of PD0325901. At this time, trametinib and selumetinib have been extensively studied clinically as MEK inhibitors in advanced solid tumors.

Selumetinib

Preclinical studies

Selumetinib (AZD6244, ARRY-142886; AstraZeneca, PLC, London, United Kingdom) is a highly selective, ATP-uncompetitive allosteric inhibitor of both MEK1 and MEK2 and has the empirical formula of \( \text{C}_{17}\text{H}_{15}\text{BrCLFN}_{4}\text{O}_{3} \) (Figure 2). The half-maximal inhibitory concentration of selumetinib is 14.1 nmol/L against purified MEK1 in vitro, whereas no inhibition of 40 other serine/threonine and tyrosine kinases was observed at concentrations up to 10 \( \mu \)mol/L.\textsuperscript{13}

\textbf{NRAS/KRAS/BRAF mutant cancer cell lines}

Although a majority of melanomas have dysregulated MAPK pathway via \textit{BRAF} and \textit{NRAS} mutations, 90\% of pancreatic cancers, 50\% of colorectal cancers, and 25\% of non-small-cell lung cancers also have constitutively activated MAPK pathway via \textit{KRAS} mutations.\textsuperscript{14–16} Therefore, MAPK pathway inhibition by selumetinib was evaluated in other malignancies, including colorectal, pancreatic, non-small-cell lung, and hepatocellular cancer, as well as melanoma.

Phosphorylation of ERK1/2, downstream molecules of MEK, was effectively inhibited with selumetinib in melanoma, colorectal cancer, pancreatic cancer, non-small-cell lung cancer, and hepatocellular cancer cell lines harboring

---

\textbf{Figure 1} Melanoma signaling pathway.
Selumetinib and vorinostat induced a synergistic antiproliferative effect in melanoma, and vorinostat, a histone deacetylase inhibitor, was evaluated in a translational modification. The combination of selumetinib and vorinostat, a histone deacetylase inhibitor, was evaluated in a translational modification. The combination of selumetinib and vorinostat, a histone deacetylase inhibitor, was evaluated in a translational modification.

**Selumetinib-based combination treatment**

To overcome the inconsistent efficacy of selumetinib and enhance its antitumor activity, several combinatorial approaches have been studied. The combined treatment with selumetinib and cytotoxic chemotherapy such as irinotecan, docetaxel, temozolomide, and doxorubicin resulted in significant enhanced antitumor efficacy by both cell cycle arrest and apoptosis in mice xenografts of BRAF mutant melanoma, as well as KRAS mutant colon cancer, non-small-cell lung cancer, pancreatic cancer, and hepatocellular carcinoma. Gopal et al have reported that the PI3K/AKT pathway plays a critical role in the antitumor efficacy of selumetinib in BRAF mutant melanoma, and inhibition of PI3K/AKT pathway results in synergistic antitumor activity with selumetinib. Because it has been reported that activation of Wnt/β-catenin signaling pathway inhibits tumor growth in mouse models of melanoma, the combinatorial effect of Wnt/β-catenin activation and selumetinib was examined. The combination of selumetinib and WNT3A, a ligand of Wnt/β-catenin pathway, induced apoptosis of melanoma cell lines harboring BRAF or NRAS mutations by degradation of AXIN1, a negative regulator of Wnt/β-catenin signaling. Apoptosis-resistant BRAF and NRAS mutant melanoma cell lines were able to sensitize to selumetinib by knock-down of AXIN1 expression with siRNA in the study.

Recently, histone deacetylases have been reported to be up-regulated in cancer cells and lead to suppression of tumor suppressor gene expression such as p53 by a post-translational modification. The combination of selumetinib and vorinostat, a histone deacetylase inhibitor, was evaluated in KRAS mutant colorectal cancer. The treatment with selumetinib plus vorinostat induced a synergistic antiproliferative activity against KRAS mutant colorectal cancer cell lines by the mechanism of apoptosis, cell-cycle arrest, and reduced cellular migration and VEGF-A secretion in vitro and in vivo.

**Uveal melanoma**

Although uveal melanomas rarely have BRAF and NRAS mutations, the MAPK pathway is constitutively activated by GNAQ or GNA11 mutations that occur in approximately 80% of primary uveal melanomas. Because direct pharmacologic targeting of GNAQ/GNA11 mutations is not feasible, inhibition of the key downstream effectors of MAPK pathway has been studied. In vitro studies have demonstrated that selumetinib monotherapy is not effective in inducing antitumor activity in uveal melanoma cell lines because of reciprocal activation of the c-JUN or PI3K/AKT pathway, which is associated with cell proliferation, tumor cell invasion, and drug resistance. The combination of either c-Jun inhibition or PI3K/AKT inhibitors with selumetinib resulted in the significant induction of apoptosis in uveal melanoma cell lines. Another preclinical study demonstrated that the combination of selumetinib and a mammalian target of rapamycin (mTOR) inhibitor (AZD8055) which is downstream of PI3K/AKT pathway, induces tumor regression in BRAF mutant uveal melanoma cell lines but not GNAQ mutant cell lines. Unfortunately, these cell lines are likely contaminants of cutaneous melanoma cell lines because BRAF mutations are not present in uveal melanoma. The resistance to selumetinib plus AZD8055 in GNAQ mutant uveal melanoma cell lines is associated with expression of the prosurvival protein MCL1. Interestingly, there is a discrepancy between the two preclinical uveal melanoma studies using MEK inhibitors and PI3K/AKT/mTOR inhibitors. One study has shown that the combination of a MEK inhibitor (trametinib) with a PI3K inhibitor (GSK2126468) induced significant antitumor activity with a GNAQ mutant melanoma cell line, whereas the other study demonstrated that concurrent treatment of a MEK inhibitor (selumetinib) and mTOR inhibitor (AZD8055) does not result in any significant apoptosis or tumor growth suppression with the same GNAQ mutant cell line. The discrepancy of the studies may result from the different activity of each inhibitor.

**Drug development**

**Pharmacokinetics**

Initially, selumetinib was formulated as a freebase oral suspension with a median half-life of 8 hours and 100 mg twice a day of 50% maximum tolerated dose (MTD). Subsequently, a solid oral capsule formulation incorporating a hydrogen
sulfate (Hyd-Sulfate) salt was developed to facilitate patient compliance and convenience. In a phase 1 clinical study, MTD of selumetinib with Hyd-Sulfate capsule was established as 75 mg twice a day. When MTD of Hyd-Sulfate capsule (75 mg twice a day) was compared with that of freebase suspension (100 mg twice a day), the maximum plasma concentration ($C_{\text{max}}$) and the area under the concentration-time curve from 0–24 hours of Hyd-Sulfate capsule were 1,316 ng/mL and 4,454 ng × hour/mL, respectively, and for freebase suspension they were 523 ng/mL and 2,260 ng × hour/mL, respectively. The estimated oral bioavailability of the Hyd-Sulfate capsule relative to the freebase suspension was 263% (90% confidence interval, 241%–322%), which suggests a better pharmacokinetic profile of the Hyd-Sulfate capsule than the freebase formulation.

A food effect study with 75 mg twice a day of the Hyd-Sulfate formulation has demonstrated that high-fat meals reduced $C_{\text{max}}$ and area under the curve for selumetinib by 62% and 19%, respectively, and delayed the rate of absorption of selumetinib by 2.5 hours in comparison with fasting. Therefore, it is recommended that selumetinib should be taken on an empty stomach with water either 2 hours before eating or 1 hour after.

**Pharmacodynamics**

Because inhibition of ERK phosphorylation has been used as a pharmacodynamic biomarker of MEK inhibitor activity, the level of inhibition of ERK phosphorylation was measured in circulating lymphocytes and tumor samples before and after selumetinib treatment in phase 1 studies. Up to 100% inhibition of ERK phosphorylation was seen 1 hour after the first dose of selumetinib, and up to 90% of inhibition (geometric mean, 79%) was observed on day 15 and day 22 of selumetinib treatment in circulating lymphocytes. In tumor biopsy samples, selumetinib treatment induced strong inhibition of ERK phosphorylation, on average, by 79% by immunohistochemistry. However, Ki67, a proliferation marker, was not reduced consistently in tumor samples after selumetinib treatment.

**Early phase 1 studies of selumetinib**

The first phase 1 study of selumetinib used freebase formulation for 57 previously treated patients with advanced solid tumors. This trial established MTD of freebase formulation of selumetinib to be 100 mg twice a day and demonstrated significant inhibition of ERK phosphorylation in peripheral blood mononuclear cells and tumor samples after selumetinib treatment, as described earlier. Nine of 57 patients with advanced solid tumors including metastatic melanoma and medullary thyroid cancer had long-term disease stabilization. However, no objective response was observed.

In a phase 1 study of selumetinib Hyd-Sulfate oral capsule, 75 mg twice a day was established as the MTD dose, as previously described. One complete response of $BRAF\ \text{V600E}$ mutant metastatic melanoma (2.9%) and 16 stable disease (45.7%) were observed among 35 patients with advanced solid tumors who received 75 mg twice a day of selumetinib. Because this study demonstrated a better pharmacokinetic profile of the Hyd-Sulfate formulation than the freebase formulation, as discussed earlier, subsequent studies have used the Hyd-Sulfate formulation of selumetinib.

In a phase 1 open-label, randomized food effect study mentioned previously, two patients (7.1%) with metastatic melanoma had partial response.

Because preclinical studies have shown synergistic antitumor activity of selumetinib in combination with cytotoxic or molecularly targeted drugs, selumetinib-based combination therapies have been evaluated in the clinical setting. In one phase 1 study of selumetinib at 75 mg twice a day in combination with one of four drugs (dacarbazine, docetaxel, erlotinib, or temsirolimus) involving 18 patients with metastatic melanoma, five objective clinical responses (28%) were observed and all responders had $BRAF$ mutant melanoma. The choice of the combination was at the discretion of the local investigator. In the study, a median time to progression of patients with $BRAF$ mutant melanoma was 51 weeks, and for wild $BRAF$ it was 12 weeks (hazard ratio [HR], 0.22; 95% confidence interval [CI], 0.06–0.82; $P=0.02$). There is an ongoing phase 1 study of the combination of selumetinib and cediranib maleate, a vascular endothelial growth factor receptor inhibitor (AZD2171) in patients with advanced solid tumors, including melanoma, that is currently recruiting participants (NCT01364051).

**Later-stage clinical trials**

In a randomized open-label phase 2 study, efficacy of selumetinib in freebase formulation was compared with temozolomide in patients with chemotherapy-naive advanced melanoma. The primary outcome of the study was PFS. Two hundred patients were randomized to either selumetinib (100 mg twice daily in 28-day cycles) or temozolomide (200 mg/m$^2$ daily for 5 days, followed by 23 days off treatment). Objective response was observed in 6 patients (5.8%) receiving selumetinib and 9 patients (9.4%) in the temozolomide group. Among patients with $BRAF$-positive melanoma, objective response rate was similar...
between the two treatment groups (11.1% for selumetinib and 10.7% for temozolomide). Five of the six responders in the selumetinib group had \textit{BRAF} mutant melanoma. Median PFS was not different significantly between selumetinib and temozolomide (78 and 80 days, respectively).

Because MEK inhibition has better antitumor activity in melanoma harboring \textit{BRAF} mutations than wild \textit{BRAF}, clinical efficacy of Hyd-Sulfate selumetinib was evaluated in selected patients with \textit{BRAF} mutant melanoma in another phase 2 study. In addition, all patients were stratified by activation of PI3K/AKT pathway based on phosphorylated-AKT (pAKT) expression (high versus low) in the study, as PI3K/AKT pathway is one of the critical regulators of selumetinib efficacy in \textit{BRAF} mutant melanoma. The primary endpoint of the study was clinical response, and three objective clinical responses were observed in a total of 15 patients. All three responders had low pAKT expression in the study. The estimated median PFS and OS were 2.2 and 8 months in the high pAKT cohort and 7.1 and 18 months in the low pAKT cohort without statistical significance.

In a double-blind randomized phase 2 study, the combination of Hyd-Sulfate selumetinib and dacarbazine was evaluated as a first-line treatment for \textit{BRAF} mutant metastatic melanoma. Patients with metastatic melanoma harboring \textit{BRAF} mutations were randomly assigned to either selumetinib combined with dacarbazine or to dacarbazine alone, and the primary objective was to compare overall survival analyzed by intention to treat between the two groups. The objective response rate was 40% (18/45 patients) in the selumetinib plus dacarbazine group and 26% (12/46 patients) in the dacarbazine-alone group. Although OS did not differ significantly between selumetinib in combination with dacarbazine and dacarbazine alone (median, 13.9 and 10.5 months, respectively), PFS was significantly improved in the selumetinib plus dacarbazine group compared with dacarbazine alone, with a median of 5.6 and 3.0 months, respectively (HR, 0.63; 80% CI, 0.47–0.84; \(P=0.021\)).

Because uveal melanomas also have activated MAPK pathway, inhibition of MAPK pathway using MEK inhibitors has been studied in uveal melanoma. In a randomized open-label phase 2 study of freebase selumetinib versus temozolomide in patients with advanced melanoma including uveal melanoma, none of seven patients with uveal melanoma in the selumetinib group achieved clinical response. Hyd-Sulfate selumetinib was studied in a randomized phase 2 study specifically for metastatic uveal melanoma (NCT01143402). In the study, patients were randomized to receive either selumetinib or temozolomide, and all patients were stratified by \textit{GNAQ}

and \textit{GNA11} mutations. The primary endpoint of the study was PFS. Patients in the temozolomide group with disease progression were allowed to crossover to receive selumetinib. At interim analysis, the median PFS duration was 15.9 weeks, and the median OS duration was 10.8 months in the selumetinib group (\(n=47\)), regardless of mutation status, whereas the temozolomide group (\(n=49\)) had a median PFS and OS of 7.0 weeks and 9.4 months, respectively. The HR for PFS was 0.46 (95% CI, 0.30–0.71; \(P=0.0005\)), and for OS it was 0.79 (95% CI, 0.46–1.37; \(P=0.4\)).

There are several ongoing phase 2 clinical studies using selumetinib in Hyd-Sulfate formulation. One double-blind randomized phase 2 study comparing the efficacy of docetaxel plus selumetinib with docetaxel in wild \textit{BRAF} melanoma is recruiting patients in the United Kingdom (NCT01256359).

In another phase 2 study, the efficacy of the combination of selumetinib and an AKT inhibitor (MK2206) is being evaluated in patients with stage III or IV melanoma who failed prior therapy with BRAF inhibitors (NCT01519427).

The results of the phase 2 studies and ongoing clinical trials of selumetinib are summarized in Tables 1 and 2, respectively.

### Selumetinib in specific populations

#### \textit{BRAF}-positive melanoma

Several preclinical and clinical studies have demonstrated that selumetinib has better antitumor activity in \textit{BRAF}-positive melanoma than in \textit{BRAF}-negative melanoma, as discussed previously. Two BRAF inhibitors such as vemurafenib and dabrafenib have been approved by the FDA after demonstrating a survival benefit for patients with \textit{BRAF V600E/K} mutant melanoma.\textsuperscript{38} The combination of a BRAF inhibitor with a MEK inhibitor has shown better toxicity profiles and clinical benefit than monotherapy in patients with a \textit{BRAF V600E/K} mutation.\textsuperscript{41} In a phase 1/2 study of the combination of dabrafenib and trametinib versus single-agent dabrafenib in patients with \textit{BRAF V600} mutation, the response rates and median PFS duration were significantly better in the combination group than the dabrafenib-alone group (response rate, 76% versus 54%; \(P=0.03\); the median PFS: 9.4 versus 5.8 months; HR, 0.39; 95% CI, 0.25–0.62; \(P<0.001\)).\textsuperscript{41} Another phase 1 study of the combination of vemurafenib and GDC-0973, a selective MEK inhibitor, showed that all 25 evaluable BRAF inhibitor-naïve patients had tumor reduction with the combined therapy. At this time, several phase 3 studies of the combination of BRAF inhibitors and MEK inhibitors are underway.
### Table 1: Clinical efficacy data of randomized phase 2 studies of selumetinib in melanoma

<table>
<thead>
<tr>
<th>Trial and regimen</th>
<th>N</th>
<th>Treatment setting</th>
<th>Overall response rate, %</th>
<th>P-value</th>
<th>Median progression-free survival, months</th>
<th>Hazard ratio (95% confidence interval), P-value</th>
<th>Median overall survival, months</th>
<th>Hazard ratio (95% confidence interval), P-value</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selumetinib versus</td>
<td>104</td>
<td>First-line</td>
<td>5.8 versus 9.4</td>
<td>NS</td>
<td>2.6 versus 2.7</td>
<td>1.07 (0.86–1.32), 0.6</td>
<td>9.5 versus 12.3</td>
<td>1.35 (0.95–1.93), 0.9</td>
<td>37</td>
</tr>
<tr>
<td>temozolomide</td>
<td>versus</td>
<td>selumetin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low pAKT</td>
<td>5</td>
<td>First-line; BRAF V600E/K with two cohort (low versus high pAKT)</td>
<td>60</td>
<td>NS</td>
<td>7.1</td>
<td>0.63 (0.47–0.84), 0.021</td>
<td>13.9 versus 10.5</td>
<td>0.93 (0.67–1.28), 0.39</td>
<td>39</td>
</tr>
<tr>
<td>High pAKT</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td>2.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selumetinib + dacarbazine</td>
<td>45</td>
<td>First-line; BRAF V600</td>
<td>40 versus 26</td>
<td>0.081</td>
<td>5.6 versus 3</td>
<td>0.63 (0.47–0.84), 0.021</td>
<td>13.9 versus 10.5</td>
<td>0.93 (0.67–1.28), 0.39</td>
<td>39</td>
</tr>
<tr>
<td>versus dacarbazine</td>
<td>versus</td>
<td>selumetin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selumetinib versus</td>
<td>47</td>
<td>First-line; advanced uveal melanoma</td>
<td>15 versus 0</td>
<td>NS</td>
<td>3.7 versus 1.6</td>
<td>0.46 (0.3–0.71), &lt;0.001</td>
<td>10.8 versus 9.4</td>
<td>0.79 (0.46–1.37), 0.4</td>
<td>40</td>
</tr>
<tr>
<td>temozolomide</td>
<td>versus</td>
<td>selumetin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviation:** NS, not significant.
Table 2 Ongoing clinical trials of selumetinib

<table>
<thead>
<tr>
<th>Trial and regimen</th>
<th>Phase</th>
<th>Treatment setting</th>
<th>Mutation criteria</th>
<th>Primary endpoint</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01364051: selumetinib + cediranib (vascular endothelial growth factor receptor inhibitor)</td>
<td>1</td>
<td>Any</td>
<td>Any</td>
<td>Safety</td>
<td>87</td>
</tr>
<tr>
<td>NCT01143402: selumetinib versus temozolomide for metastatic uveal melanoma</td>
<td>2</td>
<td>Any; no prior MEK inhibitors</td>
<td>Any</td>
<td>PFS</td>
<td>159</td>
</tr>
<tr>
<td>NCT01256359: docetaxel + selumetinib versus docetaxel</td>
<td>2</td>
<td>Front-line</td>
<td>Wild BRAF</td>
<td>PFS</td>
<td>80</td>
</tr>
<tr>
<td>NCT01519427: selumetinib + MK2206 (AKT inhibitor)</td>
<td>2</td>
<td>BRAF inhibitors, resistant melanoma</td>
<td>BRAF V600</td>
<td>ORR</td>
<td>36</td>
</tr>
</tbody>
</table>

Abbreviations: PFS, progression-free survival; ORR, overall response rate.

of disease progression. MEK-dependent resistance has been explained by the acquisition of new NRAS or MEK mutation, overexpression of COT-1 (serine/threonine kinase protein), elevated CRAF kinase protein expression, and alternate splicing of the BRAF gene. In particular, a MEK1 mutation was identified as acquired resistance to selumetinib therapy in melanoma cell lines and tumor samples of patients treated with selumetinib. The MEK-dependent resistance can be overcome by more potent inhibition of the MAPK pathway, such as the combination of BRAF inhibitors and MEK inhibitors.

In contrast, MEK-independent resistance can develop through overexpression of MITF, which is a transcription factor and regulates melanogenesis, activation of PI3K/AKT pathway by loss of PTEN, overexpression of receptor tyrosine kinases, and secretion of hepatocyte growth factor from tumor microenvironment. In non-small-cell lung cancer cell lines, selumetinib resistance was mediated by a high level of AKT activity, and the resistance was reversed by AKT inhibition. Because MEK-independent resistance is not sensitive to MEK inhibitor monotherapy, the combined inhibition of MEK inhibitors and AKT inhibitors or MEK inhibitors plus histone deacetylase inhibitors suppressing MITF may reverse the resistance. At this time, a phase 2 study of the combination of selumetinib and an AKT inhibitor (MK2206) is being evaluated in patients with metastatic melanoma who failed prior therapy with BRAF inhibitors (NCT01519427).

Toxicities
Safety data have demonstrated that selumetinib overall appears to be well-tolerated. The most common adverse events were rash (63%–74% of patients) and fatigue (41%–68% of patients) in a dose-dependent manner in phase 1 studies. Selumetinib-induced skin reactions have been evaluated in patients with advanced melanoma in a phase 2 study. The most common acute skin reaction was papulopustular rash on the face, upper chest, and back with increased apoptotic keratinocytes and focal neutrophil infiltration histologically. In a half-side treatment experiment, one side of the face of all patients was treated with topical corticosteroid and the other side with topical antibiotics. A faster improvement of the selumetinib-associated skin reactions was observed with topical steroid than antibiotics, which suggests an inflammatory component of the rash caused by neutrophils. Diarrhea and nausea, the two most common gastrointestinal toxicities, have been reported in 48%–61% and 44%–54% of the patients, respectively. These toxicities were generally responsive to supportive care. Peripheral edema, reversible mild to moderate transaminitis, and transient and reversible blurry vision have been reported as adverse events as well. Hematologic toxicity is a rare toxicity with selumetinib. Grade 3/4 toxicities were reported up to 71% in a phase 1 study, but the majority of the toxicities were reported by only a single patient each. Grade 3/4 events reported by more than one patient were left ventricular dysfunction, nausea, vomiting, fatigue, febrile infection, pneumonia, elevation of alkaline phosphatase, elevation of y-glutamyltransferase, hypoxia, dyspnea, abdominal pain, constipation, anemia, rash, and hypertension.

Conclusion
Selumetinib is an orally available highly selective inhibitor of both MEK1 and MEK2 with a favorable toxicity profile. Preclinical data have demonstrated that MEK inhibition by selumetinib is one of the effective strategies for targeting dysregulated MAPK pathway that leads to unregulated cell proliferation and development and progression of melanoma. Clinical studies have proven the potential antitumor activity of selumetinib in a subset of melanoma patients such as BRAF mutant melanoma and uveal melanoma harboring GNAQ/GNA11 mutations. In addition, selumetinib-based combination treatment is being investigated more extensively to potentiate synergistic effects and overcome resistance. At this time, a phase 3 registration trial of selumetinib plus dacarbazine versus placebo plus dacarbazine for metastatic uveal melanoma represents the first potential indication for
this drug. If successful, selumetinib with dacarbazine will be the first treatment regimen considered for approval for metastatic uveal melanoma.

Disclosure
The authors report no conflicts of interest in this work.

References
42. Gonzalez R, Ribas A, Daud A, Pavlick A, Gajewski T, Puzanov I. Phase Ib study of vemurafenib in combination with the MEK inhibitor, GDC-0973, in patients (pts) with unresectable or metastatic BRAFV600 mutated melanoma (BRIM7). 37th European Society for Medical Oncology Congress; September 28–October 2, 2012; Vienna, Austria. Abstract 2744.